Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-02
2005-08-02
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S089000, C546S022000, C540S524000, C544S238000, C544S331000, C544S405000, C514S212010, C514S253030, C514S275000
Reexamination Certificate
active
06924292
ABSTRACT:
A compound having a partial structure represented by Formula:or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease, diabetes and the like.
REFERENCES:
patent: 3709909 (1973-01-01), Habicht et al.
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 5177085 (1993-01-01), Naef
patent: 5902824 (1999-05-01), Ulrich
patent: 6153406 (2000-11-01), Tai et al.
patent: 1275 164 (1972-05-01), None
patent: 01246272 (1989-10-01), None
Yarwood, et al. “The RACK 1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform” The Journal of Biological Chemistry 274(21):14909-14917(1999).
Okumura, et al. “cDNA Cloning and Bacterial Expression of Phospholipase A2Inhibitor PLIα From The Serum of The chinese Mamuchi,Agkistrodon blomhoffii siniticus” Biochimica et Biophysica Acta 1441 51-60 (1999).
Peter Norman “PDE4 Inhibitors 1999” Exp. Opin. Ther. Patents 9(8): 1101-1118 (1999).
de Souza, et al. “An improved synthesis of 1(2H)-isoquinolinones: Synthesis and biological activity of novel 2H-pyrano[2,3-h]isoquinolin-1,10-diones and 1(2H)-furo[2,3-h] isoquinolinones” Indian Journal of Chemistry 31B:578-582(Sep. 1992).
Christensen, et al. “I,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma” J. Med. Chem 41: 821-835(1998).
de Souza, et al. “Synthesis and biological activity of novel 1(2H)-furo[2,3-h]isoquinolinone, 1(2H)-pyrano[2,3-h]isoquinolinone and 2H-pyrano[2,3-h]isoquinoline-1,8-dione” Indian Journal of Chemistry 33b:552-555 (Jun. 1994).
Némoz et al. “Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells” FEBS Letts. 384-97-102(1996).
Fuhrmann, et al. “Identification and Function of Cyclic Nucleotide Phosphodiesterase Isoenzymes in Airway Epithelial Cells” Am. J. Respir. Cell Mol. Biol. 20:292-302 (1999).
Fujii Nobuhiro
Kawano Yasuhiko
Matsumoto Tatsumi
Tarui Naoki
Uchikawa Osamu
Aulakh Charanjit S.
Chao Mark
Ramesh Elaine M.
Takeda Chemical Industries Ltd.
LandOfFree
Furoisoquinoline derivatives, process for producing the same... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Furoisoquinoline derivatives, process for producing the same..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Furoisoquinoline derivatives, process for producing the same... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3522785